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abstract
PURPOSE This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine
surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer.
PATIENTS AND METHODS Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting
parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were
enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or
absence of a germline BRCA mutation—gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was
estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea,
and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE
post–random assignment and before disease progression. TWiST was estimated as the difference between
mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all
symptomatic grade 2 or greater AEs.
RESULTS In the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of
3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively,
compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years,
respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean
TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST
benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time
horizons.
CONCLUSION Patients who were treated with niraparib compared with RS experienced increased mean TWiST.
Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without
symptoms or symptomatic toxicities compared with control.
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INTRODUCTION
Ovarian cancer (OC) was diagnosed in 240,000
women worldwide in 2012.1 Most women are di-
agnosed with advanced cancer and prognosis is poor,
which is reflected by OC being one of the most deadly
forms of women’s cancer, with a 5-year survival rate of
47.4% and approximately 151,917 deaths in 2012.1,2
The standard of care for first-line treatment is platinum-
and taxane-based chemotherapy, which results in
high initial response rates; however, relapse rates for
women who are diagnosed with advanced OC can be
up to 95%.3,4
Given the lack of a cure for recurrent OC (ROC) and the
negative impact on patient quality of life (QoL), there is
a need for effective maintenance treatments that delay
disease progression without the toxic effects that offset
this benefit and affect patient QoL. The poly(ADP-ribose)
polymerase inhibitor (PARPi) niraparib is approved by
the US Food and Drug Administration and European
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patients with recurrent epithelial ovarian, fallopian tube, or
primary peritoneal cancer who have achieved complete or
partial response to platinum-based chemotherapy.5,6 In the
randomized controlled phase III ENGOT-OV16/NOVA trial of
niraparib, patients were categorized according to the pres-
ence or absence of a germline BRCAmutation—gBRCAmut
and non-gBRCAmut cohorts. Results demonstrated that
niraparib treatment significantly extended median progression-
free survival (PFS) in the gBRCAmut (21.0 months v 5.5
months; P, .001) and non-gBRCAmut cohorts (9.3 months v
3.9 months; P , .001).7
The ENGOT-OV16/NOVA trial demonstrated that patient
QoL remained stable during treatment and the pre-
progression period, with no significant differences observed
between treatment arms.8 Therefore, niraparib treatment
prolongs PFS compared with placebo and maintains QoL.
To explore this benefit further, this analysis estimated the
time without symptoms or toxicity (TWiST) between ni-
raparib and routine surveillance (RS) in patients with
gBRCAmut and non-gBRCAmut tumors who were enrolled
in ENGOT-OV16/NOVA. TWiST is an established method-
ology that partitions PFS into two health states and eval-
uates the tradeoff between treatment toxicity and time to
progression9,10; therefore, TWiST provides an estimate of
time when a patient is free from progression and toxicity
and thus likely to maintain a good QoL.
PATIENTS AND METHODS
Data Source
This analysis used data from the gBRCAmut and non-
gBRCAmut cohorts of ENGOT-OV16/NOVA (ClinicalTrials.gov
identifier: NCT01847274). Eligible patients were age
18 years or older; had histologically diagnosed ovarian,
fallopian tube, or primary peritoneal cancer with pre-
dominantly high-grade serous histologic features; and
received two or more platinum-based chemotherapy
regimens. Patients must have had platinum-sensitive
disease—complete or partial response and disease
progression—more than 6 months after their penultimate
platinum-based chemotherapy. Patients were randomly
assigned 2:1 to receive once-daily niraparib 300 mg or
placebo.7 Comparison with placebo was chosen to reflect
the impact of niraparib on clinical practice. As such, pla-
cebo is referred to as RS from here on. The ENGOT-OV16/
NOVA primary end point was PFS, which was defined as
the time from treatment randomization to the earliest
date of disease progression or death from any cause.
Secondary end points included patient-reported outcomes,
chemotherapy-free interval, PFS on the next line of therapy,
time to first and second subsequent therapy, and overall
survival. Efficacy data were analyzed in the intention-to-
treat population, which was defined as all patients who
underwent random assignment in each cohort. Safety data
were analyzed in the safety population, defined as all pa-
tients who received one or more doses of treatment.7
Study Participants
This analysis was performed on the intention-to-treat
population of the gBRCAmut (niraparib, n = 138; RS, n =
65) and non-gBRCAmut cohorts (niraparib, n = 234; RS,
n = 116) from ENGOT-OV16/NOVA. Patient baseline
characteristics were balanced across cohorts (Data Sup-
plement Table S1).7 One patient in the gBRCAmut cohort
was excluded from the niraparib data set as the patient
had only received first-line chemotherapy before initiating
niraparib. One patient from the non-gBRCAmut cohort
was excluded from the RS data set as no prior therapy
line was recorded.
Statistical Analysis
Statistical analysis was performed using RStudio, version
1.138 (Boston, MA).11
PFS. Patient-level data (database lock: June 20, 2016)
from ENGOT-OV16/NOVA were used to derive Kaplan-
Meier PFS curves for niraparib and RS for the gBRCA-
mut and non-gBRCAmut cohorts.
The time horizon for PFS extrapolation was based on expert
clinical opinion such that patients could be progression free
for up to 20 years. In addition, a recent National Institute for
Health and Care Excellence (NICE) appraisal reported that
it is biologically plausible for patients receiving niraparib to
be progression free more than 10 years.12 Therefore, the
base case analysis assumed that patients could be pro-
gression free for up to 20 years. In addition, the assumption
that patients could be progression free for up to 5, 10, and
15 years was explored in sensitivity analyses.
PFS extrapolation was performed over a 20-year time ho-
rizon by fitting standard parametric survival distributions to
niraparib and RS Kaplan-Meier PFS data. NICE Decision
Support Unit guidelines were followed.13 The best-fitting
distribution between treatment arms for each cohort, re-
ferred to as the base case, was selected on the basis of
clinical plausibility and statistical and visual fit. The de-
termination of the best-fitting distribution is further reported
in the Data Supplement.
The generalized gamma distribution was identified as the
statistically best-fitting distribution across treatment arms
for both cohorts. Visual inspection confirmed that the
generalized gamma distribution fit the data well (Fig 1).
Clinical plausibility was assessed by comparing 5-year
survival estimates with long-term survival available in
platinum-sensitive ROC (PSROC) for PARPi. Study 19
olaparib data demonstrated that approximately 16% and
14% of patients with BRCAmut and BRCA wild-type tu-
mors, respectively, remained on treatment—that is, pro-
gression free—at 5 years.14 Of the six standard parametric
survival distributions, the generalized gamma distribution
most closely modeled long-term survival from Study 19,
with 22% and 13% of patients progression free at 5 years in
the gBRCAmut and non-gBRCAmut cohorts, respectively.
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Thus, this analysis used the generalized gamma distribu-
tion for the base case PFS extrapolation.
Mean PFS for niraparib and RS was calculated as the area
under the curve (Data Supplement, Equation S1).
Toxicity and TWiST. In ENGOT-OV16/NOVA, safety was
assessed by adverse event (AE) monitoring, laboratory
tests, vital signs, and physical examinations.7 AEs were
collected from the time of consent through treatment
discontinuation as a result of disease progression or un-
acceptable toxicity. New serious AEs were collected for
30 days after treatment discontinuation.7 Few patients
discontinued therapy because of AEs (niraparib, 15%;
placebo, 2%), and the most common AEs were managed
with dose reductions and treatment interruptions.7 Disease
progression was the primary reason for treatment discon-
tinuation (niraparib, 52%; placebo, 81%).
To estimate the mean time with toxicity, three symptomatic
grade 2 or greater AEs which patients experienced in
ENGOT-OV16/NOVA were included: fatigue (niraparib, n =
80 [21.8%]; RS, n = 15 [8.4%]; P , .001), nausea (ni-
raparib, n = 78 [21.3%]; RS, n = 15 [8.4%]; P = .003), and
vomiting (niraparib, n = 25 [6.8%]; RS, n = 8 [4.5%]; P =
.3413). These AEs were consistent with those selected in
the published SOLO-2 trial TWiST analysis10 and were
among some of the most common symptomatic AEs
experienced by patients in ENGOT-OV16/NOVA. Therefore,
it could be expected that these AEs would have the greatest
impact on QoL. The impact of hematologic AEs—for ex-
ample, anemia, neutropenia, and thrombocytopenia—was
not assessed, as a previous analysis concluded that they
had no significant effect on QoL in ENGOT-OV16/NOVA.8
Time with toxicity for each patient was calculated as the
number of days a patient experienced grade 2 or greater
fatigue, nausea, or vomiting after random assignment and
before disease progression. The number of days a patient
experienced one of these AEs was calculated by sub-
tracting the AE end date from the start date (Eq 1).
AE duration ¼ end date2 start date: (1)
Multiple occurrences of these AEs experienced by a patient
over the same time period were not counted twice. As such,
the earliest start date and the latest end date were taken. In
cases in which only the month and year were reported for
the AE start or end date, data were imputed as the first day
of that month (niraparib, n = 1; RS, n = 1). AEs were ex-
cluded if they ended before randomization or began after
disease progression. For AEs that began before randomi-
zation, the start date was set to the patient’s random as-
signment date. For AEs that extended beyond disease
progression, the end date was truncated at disease
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FIG 1. Kaplan-Meier (KM) curves for progression-free survival (PFS) and generalized gamma distributions over a 20-year time horizon for the (A)
gBRCAmut and (B) non-gBRCAmut cohorts, and KM curves for time with toxicity (TOX) for the (C) gBRCAmut and (D) non-gBRCAmut cohorts.
gBRCAmut, germline BRCA mutation; RS, routine surveillance.
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progression. Time with toxicity was calculated for 202
patients (niraparib, n = 137; RS, n = 65) and 349 patients
(niraparib, n = 234; RS, n = 115) in the gBRCAmut and
non-gBRCAmut cohorts, respectively.
Kaplan-Meier time with toxicity curves were estimated for
niraparib and RS for both cohorts (Fig 1). Mean time with
toxicity was calculated as the restricted Kaplan-Meier mean
(Data Supplement, Equation S1).
Mean TWiST was estimated as the difference between
mean PFS and mean time with toxicity for each arm (Eq 2).
The mean TWiST difference between niraparib and RS was
calculated as the difference between mean TWiST for
niraparib and RS.
Mean TWiST ¼ mean PFS2mean time with toxicity : (2)
Sensitivity Analyses
Sensitivity analyses assessed the impact of alternative PFS
distributions, PFS time horizon, and the inclusion of all
symptomatic grade 2 or greater AEs on the mean TWiST
difference between niraparib and RS.
To assess the impact of different PFS distributions, alter-
native distributions were selected by considering statisti-
cal and visual fit and clinical plausibility. Two additional
standard parametric survival distributions—log-normal
and log-logistic—were explored as they closely modeled
5-year survival data available from Study 19 (log-normal:
gBRCAmut, 11.46%; non-gBRCAmut, 2.91%; log-logistic:
gBRCAmut, 11.03%; non-gBRCAmut, 3.98%).14 In addi-
tion, both distributions were a good statistical and visual fit
to the observed data for both cohorts (Data Supplement,
Tables S2–S3, Fig. S1–S4).
Flexible PFS distributions were also explored per NICE
Decision Support Unit guidelines and published
literature.13,15 Two distributions—normal k = 1 and odds
k = 3—were explored as they closely modeled 5-year
survival data available from Study 19 for both cohorts
(normal k = 1: gBRCAmut, 17.75%; non-gBRCAmut,
9.38%; odds k = 3: gBRCAmut, 20.54%, non-gBRCAmut,
9.21%).14 Both distributions were a good statistical fit to the
observed data for both cohorts (Data Supplement Tables
S4-S5). The Data Supplement (Fig S5-S8) shows that
distributions fit the observed data well.
In addition, sensitivity analyses were performed on the PFS
time horizon, where all patients were assumed to have
experienced disease progression by 5, 10, or 15 years.
Finally, the inclusion of all symptomatic grade 2 or greater
AEs experienced by more than 10% of patients in either
treatment arm of ENGOT-OV16/NOVA (Table 1) was
explored.
Validation
The TWiST methodology underwent internal and external
validation. PFS extrapolation estimates were validated
against published long-term survival data in PSROC for
PARPi.14 In addition, modeled outcomes were validated
using median survival time to align with the reporting of
ENGOT-OV16/NOVA, which is standard practice in clinical
trials. The analysis was conducted internally by two in-
dependent analysts (L.W. and H.G.), and the inputs were
checked for accuracy by TESARO: A GSK Company
(Waltham, MA). An external statistician reviewed the ap-
proach and provided suggestions for improvement, which
included Kaplan-Meier toxicity curves and flexible PFS
methodology. All feedback obtained was incorporated into
the final analysis and this publication.
RESULTS
Base Case Results
Base case PFS extrapolation distributions—generalized
gamma over 20 years—and Kaplan-Meier time with toxicity
curves are presented in Figure 2 for niraparib and RS.
Table 2 lists mean PFS, mean time with toxicity, and the
estimated mean TWiST difference between niraparib and
RS for both cohorts.
For the gBRCAmut cohort, niraparib was associated with
a mean PFS benefit of 4.14 years and a mean time with
toxicity of 0.31 years, which is equivalent to a mean TWiST
of 3.83 years. In addition, RS was associated with mean
PFS and mean time with toxicity of 0.91 and 0.03 years,
respectively, which is equivalent to a mean TWiST of 0.88
years. Hence, niraparib treatment resulted in a mean
TWiST benefit of 2.95 years compared with RS.
For the non-gBRCAmut cohort, niraparib was associated
with a mean PFS of 2.59 years and amean time with toxicity
of 0.13 years, which is equivalent to a mean TWiST of 2.46
years. In addition, RS was associated with mean PFS and
mean time with toxicity of 1.14 and 0.02 years, respectively,
which is equivalent to a mean TWiST of 1.12 years. Hence,
niraparib treatment resulted in a mean TWiST benefit of
1.34 years compared with RS.
Sensitivity Analyses
For all sensitivity analyses, niraparib demonstrated a con-
sistent mean TWiST benefit compared with RS when ex-
amining PFS at 5, 10, and 15 years (Table 2 and Data
Supplement Fig S9-S25). When extrapolated PFS was
modeled with more conservative estimates, mean TWiST
benefit ranged from 1.15 to 3.65 years and 0.52 to
1.23 years for the gBRCAmut and non-gBRCAmut cohorts,
respectively. When all symptomatic grade 2 or greater AEs
were included, mean TWiST benefit was 3.01 and 1.22 for
the gBRCAmut and non-gBRCAmut cohorts, respectively.
Validation
Median modeled and observed PFS from ENGOT-OV16/
NOVA were similar for both niraparib and RS for gBRCAmut
(niraparib: modeled v observed, 21.0 v 21.0 months; RS:
modeled v observed, 5.52 v 5.5months) and non-gBRCAmut
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cohorts (niraparib: modeled v observed, 9.26 v 9.3 months;
RS: modeled v observed, 3.91 v 3.9 months).7
DISCUSSION
This analysis sought to evaluate the difference in TWiST
between niraparib and RS in the maintenance treatment of
patients with PSROC. TWiST is the amount of time—
measured in years—during which patients are progression
and toxicity free and thus likely to maintain good QoL. Mean
PFS extrapolated from ENGOT-OV16/NOVA over a 20-year
time horizon demonstrated that patients receiving ni-
raparib, compared with RS, experienced increased mean
PFS in both cohorts. Sensitivity analyses were performed at
additional clinically relevant 5-, 10-, and 15-year PFS
timeframes, demonstrating improved TWIST in niraparib-
treated patients. Furthermore, subtracting the mean time
with toxicity for grade 2 or greater fatigue, nausea, and
vomiting from mean PFS resulted in an increased mean
TWiST. Base case results showed that niraparib was as-
sociated with a mean TWiST benefit compared with RS.
These TWiST benefits demonstrate that patients receiving
niraparib will maintain good QoL. Specifically, compared
with RS, patients with gBRCAmut and non-gBRCAmut
tumors who receive niraparib will gain 2.95 years and 1.34
years, respectively, during which they are progression
and toxicity free. In addition, results demonstrate that the
mean TWiST for niraparib-treated patients is more than
four-fold and two-fold greater than the mean TWiST for
patients receiving RS in the gBRCAmut and non-gBRCAmut
cohorts, respectively.
Robustness of the niraparib TWiST benefit compared with
RS was confirmed through consistency across all sensitivity
analyses in both cohorts. The greatest mean TWiST benefit
observed in these sensitivity analyses for niraparib, com-
pared with RS, was 3.65 years and 1.23 years for the
gBRCAmut and non-gBRCAmut cohorts, respectively.
When alternative PFS estimates were considered, niraparib
mean TWiST was up to five-fold and two-fold greater than
the RS mean TWiST in the gBRCAmut and non-gBRCAmut
cohorts, respectively. In addition, when all grade 2 or
greater symptomatic AEs were considered, niraparib mean
TWiST was more than four-fold and two-fold greater than
the RS mean TWiST in the gBRCAmut and non-gBRCAmut
cohorts, respectively. As a result of this TWiST benefit,
TABLE 1. Incidence of All Symptomatic Grade $ 2 Adverse Events Experienced by $ 10% of Patients in Either Treatment Arm by Cohort of
ENGOT-OV16/NOVA
Adverse Event
gBRCAmut Cohort Non-gBRCAmut Cohort
Niraparib (n = 136) RS (n = 65) P Niraparib (n = 231) RS (n = 114) P
Fatigue 43 (31.6) 8 (12.3) .0031 73 (31.6) 13 (11.4) , .001
Nausea 30 (22.1) 6 (9.2) .0303 48 (20.8) 9 (7.9) .0020
Hypertension 26 (19.1) 4 (6.2) .0189 38 (16.5) 3 (2.6) , .001
Constipation 17 (12.5) 2 (3.1) .0384 26 (11.3) 6 (5.3) .0780
Headache 15 (11.0) 2 (3.1) .0628 4 (1.7) 1 (0.9) 1.0000
Vomiting 14 (10.3) 1 (1.5) .0405 11 (4.8) 7 (6.1) .6116
Abdominal pain 10 (7.4) 5 (7.7) 1.0000 21 (9.1) 12 (10.5) .6990
Urinary tract infection 8 (5.9) 4 (6.2) 1.0000 16 (6.9) 4 (3.5) .2313
Dyspepsia 7 (5.1) 1 (1.5) .4412 5 (2.2) 1 (0.9) .6679
Back pain 7 (5.1) 2 (3.1) .7210 10 (4.3) 5 (4.4) 1.0000
Dyspnea 6 (4.4) 0 .1799 16 (6.9) 3 (2.6) .1327
Decreased appetite 6 (4.4) 1 (1.5) .4319 16 (6.9) 2 (1.8) .0425
Diarrhea 5 (3.7) 2 (3.1) 1.0000 8 (3.5) 5 (4.4) .7653
Arthralgia 5 (3.7) 2 (3.1) 1.0000 8 (3.5) 3 (2.6) 1.0000
Insomnia 5 (3.7) 0 .1770 13 (5.6) 1 (0.9) .0411
Nasopharyngitis 4 (2.9) 1 (1.5) 1.0000 5 (2.2) 1 (0.9) .6679
Abdominal distension 2 (1.5) 1 (1.5) 1.0000 6 (2.6) 4 (3.5) .7353
Dizziness 2 (1.5) 1 (1.5) 1.0000 6 (2.6) 0 .1836
Cough 2 (1.5) 0 1.0000 3 (1.3) 0 .5536
Myalgia 1 (0.7) 1 (1.5) .5433 5 (2.2) 2 (1.8) 1.0000
Palpitations 1 (0.7) 0 1.0000 5 (2.2) 0 .1753
NOTE. Data provided as No. (%) unless otherwise noted.
Abbreviations: gBRCAmut, germline BRCA mutation; RS, routine surveillance.
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patients receiving niraparib spend more time progression
and toxicity free with respect to grade 2 or greater fatigue,
nausea, and vomiting than do patients receiving RS. This
analysis demonstrates that niraparib treatment maintained
QoL among progression-free patients, which is consistent
with a previous analysis that showed that patients receiving
niraparib had stable QoL during the preprogression period.
Furthermore, all symptoms as measured by the Functional
Assessment of Cancer Therapy–Ovarian Symptom Index,
with the exception of nausea, remained stable or improved
over time with niraparib treatment.8 ROC has been asso-
ciated with a negative psychological and physical impact on
patients, particularly as patients receive additional lines of
subsequent chemotherapy.16 Therefore, as PFS decreases
with each subsequent line of chemotherapy,17 and sub-
sequent chemotherapy is associated with burdensome AEs
and a negative impact on QoL, there is a need for an al-
ternative to RS for the maintenance treatment of patients
with PSROC. Effective PARPis, such as niraparib, which
can extend PFS without negatively affecting QoL, can
significantly improve the prognosis of PSROC compared
with RS.
This publication reports one of the first TWiST analyses
conducted for a PARPi for the maintenance treatment of
patients with PSROC and is the first TWiST analysis that
evaluates both gBRCAmut and non-gBRCAmut pop-
ulations. The only other published TWiST analysis—by
Friedlander et al10—evaluated the TWiST difference be-
tween olaparib and placebo in the SOLO-2 trial; however,
these results are not comparable with those presented here
as a result of a different methodology used. Friedlander
et al10 used PFS trial data only, whereas our study ex-
trapolated PFS. Furthermore, the TWiST difference be-
tween olaparib and placebo was limited to gBRCAmut
patients only because of trial eligibility.10
The main strength of this analysis is that the clinical ev-
idence base can be considered to be representative of
real-world patients with PSROC as data were sourced
directly from patients with PSROC who were enrolled in
ENGOT-OV16/NOVA.7 In addition, PFS distributions
modeled clinically realistic estimates for PFS, which
closely match published long-term survival data reported
in PSROC for PARPi.14 Furthermore, this analysis con-
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FIG 2. Kaplan-Meier curves for time with toxicity (TOX), mean progression-free survival (PFS) generalized gamma distributions, and mean time without
symptoms or toxicity (TWiST) for (A) niraparib and (B) routine surveillance (RS) in the gBRCAmut cohort and for (C) niraparib and (D) RS in the non-
gBRCAmut cohort over a 20-year time horizon. gBRCAmut, germline BRCA mutation.
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extrapolation of ENGOT-OV16/NOVA Kaplan-Meier PFS
data, as opposed to comparing mean time with toxicity
with restricted mean PFS only, thereby estimating the
complete TWiST benefit expected for patients. Finally, this
analysis has been demonstrated to be robust, as a TWiST
benefit with niraparib was consistent across all sensitivity
analyses performed.
This analysis has some limitations. The base case PFS was
extrapolated over 20 years. Although it is unrealistic that
long-term PFS would align with this cutoff point, this was
based on expert clinical opinion and was accepted in two
previous health technology appraisal submissions.18,19
Furthermore, the impact of alternative PFS estimates
was explored through sensitivity analyses. Results in-
dicated that patients who were treated with niraparib still
experienced a TWiST benefit compared with RS even when
more conservative PFS estimates were modeled. An ad-
ditional limitation is that only the most common symp-
tomatic non-hematologic grade 2 or greater AEs were
included in the base case analysis. However, all symp-
tomatic grade 2 or greater AEs experienced by more
than 10% of ENGOT-OV16/NOVA patients was explored
in a sensitivity analysis. These results demonstrated that
niraparib-treated patients continue to experience an
increased mean TWiST compared with RS, with the
gBRCAmut mean TWiST increasing with respect to the
base case analysis because of a smaller proportional in-
crease in niraparib toxicity compared with RS. This is in
agreement with results of a previous analysis in which
a higher proportion of patients receiving RS reported pain
compared with niraparib-treated patients.8
Future analyses could include a quality-adjusted TWiST
analysis when mature overall survival data are available
from ENGOT-OV16/NOVA. Moreover, an analysis of the
safety profile of niraparib in ENGOT-OV16/NOVA recom-
mended that patients with a baseline body weight of less than
77 kg or platelet count less than 150,000/mLmay benefit from
a 200-mg per day starting dose.20 Subsequent investigations
could focus on the TWiST difference with this alternative
starting dose.
TWiST estimates from ENGOT-OV16/NOVA indicate that
niraparib-treated patients experienced increased mean
TWiST compared with patients receiving RS. Therefore, pa-
tients receiving niraparib compared with control in ENGOT-
OV16/NOVA experienced more time without symptoms or
symptomatic toxicities and thus have the potential to expe-
rience longer undiminished QoL.
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